CHEK2 and Familial prostate cancer: Some clinical laboratories, such as Ambry Genetics, Invitae, and GeneDx, offer prostate cancer-specific panels that include the following genes: ATM, BRCA1, BRCA2, CHEK2, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, and TP53. Evidence is emerging that genetic information can guide treatment modalities, hence the need to better understand genetic risk factors associated with the risk of aggressive prostate cancer.